Go here to read the rest:
Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators - PR Newswire
Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators Citizen Tribune
More Than 99% Of US Dogs Have A Behavior Problem, Texas A&M Researcher Finds Texas A&M Today
See the original post:
More Than 99% Of US Dogs Have A Behavior Problem, Texas A&M Researcher Finds - Texas A&M Today
East Texas vet tells what to watch for during cold weather in arthritic pets KTRE
The rest is here:
East Texas vet tells what to watch for during cold weather in arthritic pets - KTRE
East Texas vet tells what to watch for during cold weather in arthritic pets KLTV
Go here to read the rest:
East Texas vet tells what to watch for during cold weather in arthritic pets - KLTV
The Austin Chronic: Texas A&Ms Hemp Breeding Program Adds Drought-Resistant Genetics to the National Collection Austin Chronicle
Read more here:
The Austin Chronic: Texas A&Ms Hemp Breeding Program Adds Drought-Resistant Genetics to the National Collection - Austin Chronicle
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024.
NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 6-10, 2024 in Houston, Texas and virtually.
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format.
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually.
Go here to see the original:
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024